Carcinoma, Small-Cell Lung Clinical Trial
Official title:
Phase 1 Trial of Dosimetry Guided 212Pb-pentixather Radioligand Therapy in Patients With Atypical Lung Carcinoids and Neuroendocrine Carcinomas
This is a first-in-human clinical trial evaluating the safety of an alpha-radiation treatment (Lead-212 labelled Pentixather) in patients who have been diagnosed with, and previously treated, for atypical carcinoid lesions of the lung.
This is a study to determine what dose is acceptably safe for further testing. In this study, participants are asked to: - undergo SPECT/CT imaging with Lead-203 Pentixather (a radiotracer) to ensure the tumor lesions have the needed receptors - undergo serial blood sampling for during and after the SPECT/CT scan for radiation and dosimetry calculations (to determine how much of the Lead-212 Pentixather to administer) - receive up to 2 infusions of arginine & lysine as a kidney protectant - receive up to 2 infusions of Lead-212 Pentixather, 6 weeks between each infusion - undergo imaging at 3 months post treatment to determine disease response ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01284348 -
To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT00923884 -
Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer
|